Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / NVS - XOMA down 14% on FDA rejection of CV claim for canakinumab by licensee Novartis


NVS - XOMA down 14% on FDA rejection of CV claim for canakinumab by licensee Novartis

  • Thinly traded micro cap XOMA (XOMA -14%) is down on almost 50% higher volume, albeit on turnover of only 129K shares, in apparent reaction to Novartis' (NVS +1%) disclosure that it received a CRL from the FDA (Q3 report, page 6) in response to its application seeking a cardiovascular risk reduction claim for ACZ885 (canakinumab).
  • More news on: XOMA Corporation, Novartis AG, Healthcare stocks news, Stocks on the move,
  • Read more ...
Stock Information

Company Name: Novartis AG
Stock Symbol: NVS
Market: NYSE
Website: novartis.com

Menu

NVS NVS Quote NVS Short NVS News NVS Articles NVS Message Board
Get NVS Alerts

News, Short Squeeze, Breakout and More Instantly...